GNMX

Aevi Genomic Medicine, Inc.
GNMX

Overview Fund Activity
Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

45 hedge funds and large institutions have $14.6M invested in Aevi Genomic Medicine, Inc. in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 10 closing their positions.

Holders
45
Holders Change
-4
Holders Change %
-8.16%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
9
Reduced
12
Closed
10
Calls
$12K
Puts
–
Net Calls
+$12K
Net Calls Change
+$13K

Top Buyers

1
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$6.6M
2
Renaissance Technologies
2
Renaissance Technologies
New York
$112K
3
VAM
3
Verity Asset Management
North Carolina
$28K
4
Wells Fargo
4
Wells Fargo
California
$172K
5
Citadel Advisors
5
Citadel Advisors
Florida
$34K

Top Sellers

1
BBA
1
Baker Bros. Advisors
New York
$4.87M
2
Vanguard Group
2
Vanguard Group
Pennsylvania
$911K
3
2L
3
22NW LP
Washington
$0
4
NCMW
4
Northern Capital Management (Wisconsin)
Wisconsin
$0
5
EMG
5
ETF Managers Group
New Jersey
$0
Name Market Value Shares Shares
Change 		Shares
Change %
Simplex Trading
51
Simplex Trading
Illinois
$0 29 -200 -87%
Deutsche Bank
52
Deutsche Bank
Germany
$0 69 – –
Barclays
53
Barclays
United Kingdom
$0 169 – –
TRCT
54
Tower Research Capital (TRC)
New York
$0 61 +61 New
CIBC Private Wealth Group
55
CIBC Private Wealth Group
Georgia
$0 200 +200 New
1 2
3